United States - English - NLM (National Library of Medicine)

mutual pharmaceutical company, inc. - tolmetin sodium (unii: 02n1tzf99f) (tolmetin - unii:d8k2jpn18b) - tolmetin 400 mg - carefully consider the potential benefits and risks of tolmetin sodium and other treatment options before deciding to use tolmetin sodium. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings ). tolmetin sodium is indicated for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis. tolmetin sodium is indicated in the treatment of acute flares and the long-term management of the chronic disease. tolmetin sodium is also indicated for treatment of juvenile rheumatoid arthritis. the safety and effectiveness of tolmetin sodium have not been established in pediatric patients under 2 years of age (see precautions: pediatric use and dosage and administration ). tolmetin sodium is contraindicated in patients with known hypersensitivity to tolmetin sodium. tolmetin sodium should not be given to patients who have experienced asthma, urticaria or allergic-type reactions after taking aspirin or other nsaids. severe, rarely fatal, an

United States - English - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - tolmetin sodium (unii: 02n1tzf99f) (tolmetin - unii:d8k2jpn18b) - tolmetin 400 mg - carefully consider the potential benefits and risks of tolmetin sodium capsules, usp and other treatment options before deciding to use tolmetin sodium capsules. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings). tolmetin sodium capsules are indicated for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis. tolmetin sodium capsules are indicated in the treatment of acute flares and the long-term management of the chronic disease. tolmetin sodium capsules are also indicated for treatment of juvenile rheumatoid arthritis. the safety and effectiveness of tolmetin sodium capsules have not been established in pediatric patients under 2 years of age (see precautions: pediatric use and dosage and administration). tolmetin sodium capsules are contraindicated in patients with known hypersensitivity to tolmetin sodium. tolmetin should not be given to patients who have experienced asthma, urticaria or allergic-type reactions

United States - English - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - tolmetin sodium (unii: 02n1tzf99f) (tolmetin - unii:d8k2jpn18b) - tolmetin 600 mg - carefully consider the potential benefits and risks of tolmetin sodium tablets, usp and other treatment options before deciding to use tolmetin sodium tablets. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings). tolmetin sodium tablets are indicated for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis. tolmetin sodium tablets are indicated in the treatment of acute flares and the long-term management of the chronic disease. tolmetin sodium tablets are also indicated for treatment of juvenile rheumatoid arthritis. the safety and effectiveness of tolmetin sodium tablets have not been established in pediatric patients under 2 years of age (see precautions: pediatric use and dosage and administration). tolmetin sodium tablets are contraindicated in patients with known hypersensitivity to tolmetin sodium. tolmetin should not be given to patients who have experienced asthma, urticaria or allergic-type reactions after t

United States - English - NLM (National Library of Medicine)

stat rx usa llc - tolmetin sodium (unii: 02n1tzf99f) (tolmetin - unii:d8k2jpn18b) - tolmetin sodium 600 mg - carefully consider the potential benefits and risks of tolmetin sodium tablets and other treatment options before deciding to use tolmetin sodium tablets. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings). tolmetin sodium tablets are indicated for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis. tolmetin is indicated in the treatment of acute flares and the long-term management of the chronic disease. tolmetin is also indicated for treatment of juvenile rheumatoid arthritis. the safety and effectiveness of tolmetin have not been established in pediatric patients under 2 years of age (see precautions: pediatric use and dosage and administration). tolmetin is contraindicated in patients with known hypersensitivity to tolmetin sodium. tolmetin should not be given to patients who have experienced asthma, urticaria or allergic-type reactions after taking aspirin or other nsaids. severe, rarely fatal, anaph

United States - English - NLM (National Library of Medicine)

rising pharma holdings, inc. - tolmetin sodium (unii: 02n1tzf99f) (tolmetin - unii:d8k2jpn18b) - carefully consider the potential benefits and risks of tolmetin sodium tablets, usp and other treatment options before deciding to use tolmetin sodium tablets. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings). tolmetin sodium tablets are indicated for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis. tolmetin sodium tablets are indicated in the treatment of acute flares and the long-term management of the chronic disease. tolmetin sodium tablets are also indicated for treatment of juvenile rheumatoid arthritis. the safety and effectiveness of tolmetin sodium tablets have not been established in pediatric patients under 2 years of age (see precautions: pediatric use and dosage and administration). tolmetin sodium tablets are contraindicated in patients with known hypersensitivity to tolmetin sodium. tolmetin should not be given to patients who have experienced asthma, urticaria or allergic-type re

United States - English - NLM (National Library of Medicine)

rising pharma holdings, inc. - tolmetin sodium (unii: 02n1tzf99f) (tolmetin - unii:d8k2jpn18b) - carefully consider the potential benefits and risks of tolmetin sodium capsules, usp and other treatment options before deciding to use tolmetin sodium capsules. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings). tolmetin sodium capsules are indicated for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis. tolmetin sodium capsules are indicated in the treatment of acute flares and the long-term management of the chronic disease. tolmetin sodium capsules are also indicated for treatment of juvenile rheumatoid arthritis. the safety and effectiveness of tolmetin sodium capsules have not been established in pediatric patients under 2 years of age (see precautions: pediatric use and dosage and administration). tolmetin sodium capsules are contraindicated in patients with known hypersensitivity to tolmetin sodium. tolmetin should not be given to patients who have experienced asthma, urticaria or allergic-type reactions

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - ketorolac trometamol, quantity: 30 mg - injection, solution - excipient ingredients: sodium hydroxide; sodium chloride; water for injections; ethanol - ketorolac trometamol solution for injection is indicated for the short-term management of moderately severe, acute pain following surgical procedures. the total duration of ketorolac use should not exceed five days.,it is recommended that ketorolac parenteral be used in the immediate post-operative period.,patients can then be converted to the oral formulation (dependent on their analgesic needs), as outlined in the "dosage and administration" section (refer to "conversion from parenteral to oral therapy"). the total period of treatment utilising the oral and/or intramuscular route of administration is not to exceed five days. note that oral dosage form can be available from other brand/s.,general,ketorolac trometamol solution for injection is not recommended for use as an obstetrical pre-operative medication or for obstetrical analgesia because it has not been adequately studied for use in these circumstances and because the known effects of drugs that inhibit prostaglandin biosynthesis on uterine contraction and foetal circulation.,there is no satisfactory evidence for the use of ketorolac trometamol solution for injection in acute exacerbations of chronic painful inflammatory conditions (e.g. rheumatoid or osteoarthritis).

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - ketorolac trometamol, quantity: 30 mg/ml - injection, solution - excipient ingredients: ethanol; sodium chloride; water for injections; hydrochloric acid; sodium hydroxide - ketorolac kabi is indicated for the short-term management of moderately severe, acute pain following surgical procedures. the total duration of ketorolac use should not exceed five days.,it is recommended that ketorolac parenteral be used in the immediate post-operative period. patients can then be converted to the oral formulation (dependent on their analgesic needs), as outlined in the "dose and method of administration" section (refer to "conversion from parenteral to oral therapy"). the total period of treatment utilising the oral and/or intramuscular route of administration is not to exceed five days.,general,ketorolac is not recommended for use as an obstetrical pre-operative medication or for obstetrical analgesia because it has not been adequately studied for use in these circumstances and because the known effects of drugs that inhibit prostaglandin biosynthesis on uterine contraction and foetal circulation.,there is no satisfactory evidence for the use of ketorolac in acute exacerbations of chronic painful inflammatory conditions (e.g. rheumatoid or osteoarthritis).

Australia - English - Department of Health (Therapeutic Goods Administration)

medsurge pharma pty ltd - ketorolac trometamol, quantity: 10 mg - injection - excipient ingredients: sodium chloride; sodium hydroxide; water for injections; hydrochloric acid; ethanol - ketorolac medsurge solution for injection is indicated for the short-term management of moderately severe, acute pain following surgical procedures. the total duration of ketorolac use should not exceed five days. it is recommended that ketorolac parenteral be used in the immediate post-operative period. patients can then be converted to the oral formulation (dependent on their analgesic needs), as outlined in the section 4.2 dose and method of administration (refer to conversion from parenteral to oral therapy). the total period of treatment utilising the oral and/or intramuscular route of administration is not to exceed five days. note that oral dosage forms are available from other brands.,general,ketorolac medsurge solution for injection is not recommended for use as an obstetrical pre-operative medication or for obstetrical analgesia because it has not been adequately studied for use in these circumstances and because the known effects of drugs that inhibit prostaglandin biosynthesis on uterine contraction and foetal circulation.,there is no satisfactory evidence for the use of ketorolac medsurge solution for injection in acute exacerbations of chronic painful inflammatory conditions (e.g. rheumatoid or osteoarthritis).

Australia - English - Department of Health (Therapeutic Goods Administration)

medsurge pharma pty ltd - ketorolac trometamol, quantity: 30 mg - injection - excipient ingredients: sodium chloride; ethanol; sodium hydroxide; hydrochloric acid; water for injections - ketorolac medsurge solution for injection is indicated for the short-term management of moderately severe, acute pain following surgical procedures. the total duration of ketorolac use should not exceed five days. it is recommended that ketorolac parenteral be used in the immediate post-operative period. patients can then be converted to the oral formulation (dependent on their analgesic needs), as outlined in the section 4.2 dose and method of administration (refer to conversion from parenteral to oral therapy). the total period of treatment utilising the oral and/or intramuscular route of administration is not to exceed five days. note that oral dosage forms are available from other brands.,general,ketorolac medsurge solution for injection is not recommended for use as an obstetrical pre-operative medication or for obstetrical analgesia because it has not been adequately studied for use in these circumstances and because the known effects of drugs that inhibit prostaglandin biosynthesis on uterine contraction and foetal circulation.,there is no satisfactory evidence for the use of ketorolac medsurge solution for injection in acute exacerbations of chronic painful inflammatory conditions (e.g. rheumatoid or osteoarthritis).